Literature DB >> 1488462

Long-term hospital treatment: a 25-year study.

A Gralnick1, C L Caton.   

Abstract

Findings from a 25-year study of admissions to a single long-term private psychiatric inpatient facility document a sharp decline in average age and an increase in concurrent diagnoses of substance abuse and personality disorders. In this case, long-term private inpatient care has survived the significant changes in mental health policy and funding practices of the past quarter century, but has shifted its focus from a more general psychiatric caseload to the seriously disturbed adolescent or young adult patient. There are numerous factors which determine every aspect of hospital treatment. Though some are easily determined, many are dimly defined and difficult to measure. At present, their effect on patient progress is obscure. These factors, discussed in some detail, may be internal and peculiar to an institution itself. A dialogue is initiated for the insight it furnishes about the changes that have occurred in hospital treatment.

Entities:  

Mesh:

Year:  1992        PMID: 1488462     DOI: 10.1007/bf01065990

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  4 in total

1.  Profile of 1,300 admissions to Central Neuropsychiatric Hospital Association Collaborative Research Hospitals.

Authors:  G A Whitmarsh; S R Thorward; J Muller; E Cardona; A Keskiner
Journal:  Psychiatr Hosp       Date:  1986

2.  Comparison of two five-year follow-up studies: 1948 to 1952 and 1967 to 1972.

Authors:  J S Bockoven; H C Solomon
Journal:  Am J Psychiatry       Date:  1975-08       Impact factor: 18.112

3.  Young adult chronic patients: an analytical review of the literature.

Authors:  L L Bachrach
Journal:  Hosp Community Psychiatry       Date:  1982-03

4.  Epidemiologic evidence for early onset of mental disorders and higher risk of drug abuse in young adults.

Authors:  K A Christie; J D Burke; D A Regier; D S Rae; J H Boyd; B Z Locke
Journal:  Am J Psychiatry       Date:  1988-08       Impact factor: 18.112

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.